-+ 0.00%
-+ 0.00%
-+ 0.00%
Arrowhead's Redemplo Wins UK Approval for Rare Cholesterol Disorder
Share
Listen to the news
Arrowhead's Redemplo Wins UK Approval for Rare Cholesterol Disorder
  • Arrowhead Pharmaceuticals’ REDEMPLO (plozasiran) received UK marketing authorization to reduce triglycerides in adults with familial chylomicronemia syndrome alongside diet.
  • NICE recommended NHS funding in England and Wales for genetically confirmed cases inadequately controlled by diet and conventional triglyceride-lowering therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261027614909) on October 27, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending